De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Protagonist Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Protagonist Therapeutics heeft een totaal eigen vermogen van $541.3M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $614.6M en $73.3M. De EBIT Protagonist Therapeutics is $152.2M waardoor de rentedekking -7.5 is. Het heeft contanten en kortetermijnbeleggingen van $564.0M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | -7.5x |
| Contant | US$564.00m |
| Aandelen | US$541.32m |
| Totaal verplichtingen | US$73.31m |
| Totaal activa | US$614.63m |
Recente financiële gezondheidsupdates
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $570.9M ) PTGX } overtreffen de korte termijn passiva ( $41.6M ).
Langlopende schulden: De kortetermijnactiva PTGX ( $570.9M ) overtreffen de langetermijnschulden ( $31.7M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: PTGX is schuldenvrij.
Schuld verminderen: PTGX had 5 jaar geleden geen schulden.
Schuldendekking: PTGX heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.
Rentedekking: PTGX heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.